Berberine per Gut Dysbiosis
DPreclinical evidence that berberine modulates microbiome composition. Limited human microbiome data.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dberberine\u0026condition\u003Dgut\u002Ddysbiosis';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
In sintesi
Preclinical evidence that berberine modulates microbiome composition. Limited human microbiome data.
Key Study Findings
In Vitro
Colon-targeted self-assembled nanoparticles loaded with berberine double salt ameliorate ulcerative colitis by improving intestinal mucosal …
Dose: None
vs: Sulfasalazine; DSS-induced UC mice
Outcome: UC treatment efficacy
Effetto: Colon length 1.2x longer than sulfasalazine
None
Popolazione: DSS-induced UC murine model
Review
Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives.
Dose: None
vs: None
Outcome: None
Effetto: None
None
Popolazione: None
Review
Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent.
Dose: None
vs: None
Outcome: None
Effetto: None
None
Popolazione: None
Review
Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver …
Dose: None
vs: None
Outcome: None
Effetto: None
None
Popolazione: None
Other
Design and Activity Evaluation of Berberine-Loaded Dual pH and Enzyme-Sensitive Colon-Targeting Microparticles.
Dose: None
vs: Free berberine; DSS-induced UC model vs normal mice
Outcome: DAI scores, inflammatory cytokines, gut microbiota
Effetto: None
<0.01 (DAI); <0.05 (cytokines)
Popolazione: DSS-induced UC mouse model (male KM mice)
Other
Ulcerative Colitis Aggravates Periodontitis via Inducing Myelopoiesis.
Dose: None
vs: DSS-induced colitis + periodontitis mouse models
Outcome: Periodontal destruction and myeloid cell generation
Effetto: None
None
Popolazione: DSS-induced colitis with periodontitis mouse model
Key Statistics
2
Studi
100
Partecipanti
↑
Positive
D
Grado
Referenced Papers
International journal of …
2025
15 citazioni
Colloids and surfaces. …
2025
11 citazioni
Pharmaceuticals (Basel, Switzerland)
2025
8 citazioni
Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent.
Review
Pharmaceuticals (Basel, Switzerland)
2025
8 citazioni
Inflammatory bowel diseases
2025
2 citazioni
Pharmaceutics
2025
2 citazioni
Phytomedicine : international …
2025
2 citazioni
The Journal of …
2025
1 citazioni
European journal of …
2025
Archives of oral …
2025
Frontiers in nutrition
2025
Biomedicine & pharmacotherapy …
2024
17 citazioni
Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.
Systematic Review
International journal of …
2024
14 citazioni
Frontiers in pharmacology
2024
9 citazioni
Hepatology communications
2024
9 citazioni
Frontiers in microbiology
2024
6 citazioni
Frontiers in microbiology
2024
5 citazioni
Indian journal of …
2024
2 citazioni
Gut microbes
2023
108 citazioni
Biomedicine & pharmacotherapy …
2023
61 citazioni
International journal of …
2023
48 citazioni
Journal of ethnopharmacology
2023
29 citazioni
Frontiers in pharmacology
2023
20 citazioni
International journal of …
2023
18 citazioni
Current pharmaceutical design
2023
10 citazioni
Journal of oral …
2023
10 citazioni
Journal of neurogastroenterology …
2023
4 citazioni
Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome.
Review
Clinical and experimental …
2023
2 citazioni
Microorganisms
2022
212 citazioni
Food & function
2022
83 citazioni
Phytomedicine : international …
2022
67 citazioni
Biomaterials science
2022
34 citazioni
Microbiology spectrum
2022
25 citazioni
Brazilian journal of …
2022
12 citazioni
Pharmacological research
2021
186 citazioni
Pharmacological research
2021
147 citazioni
Acta pharmacologica Sinica
2021
63 citazioni
Frontiers in pharmacology
2021
42 citazioni
Frontiers in immunology
2021
22 citazioni
Comprehensive Physiology
2021
21 citazioni
International journal of …
2021
20 citazioni
Targeting gut barrier dysfunction with phytotherapies: Effective strategy against chronic diseases.
Review
Pharmacological research
2020
65 citazioni
Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review.
Systematic Review
Journal of integrative …
2020
33 citazioni
Pharmacological research
2019
166 citazioni
American journal of …
2019
117 citazioni
Biomedicine & pharmacotherapy …
2019
72 citazioni
Scientific reports
2019
51 citazioni
Pharmacological research
2019
31 citazioni
Science China. Life …
2018
17 citazioni
Alternative therapies in …
2017
9 citazioni
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Dosaggi di uso comune
- general:
- 500-1,500 mg/day in divided doses
- siboprotocol:
- 500 mg two to three times daily for 4 weeks (as part of herbal antimicrobial protocol)
- giantimicrobial:
- 500 mg twice daily
Limite massimo: Generally well-tolerated up to 1,500 mg/day in divided doses
Dosaggi studiati nella ricerca
| Dosaggio | Durata | Effetto | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | 6 weeks | Positive | -- |
Momento migliore per l'assunzione: With meals; divide doses throughout the day (do not take full daily dose at once)
Safety & Side Effects
Effetti collaterali segnalati
- ⚠ GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common
- ⚠ May cause uterine contractions (contraindicated in pregnancy)
- ⚠ Headache
- ⚠ Skin rash (rare)
Interazioni note
- ● Diabetes medications (berberine significantly lowers blood sugar; risk of hypoglycemia)
- ● Cyclosporine (berberine inhibits CYP3A4, increasing cyclosporine levels)
- ● Anticoagulants (may have additive blood-thinning effects)
- ● Metformin (additive glucose-lowering effect; monitor closely)
- ● Macrolide antibiotics (berberine inhibits CYP3A4)
Livello di assunzione massimo tollerabile: Generally well-tolerated up to 1,500 mg/day in divided doses
Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.
Frequently Asked Questions
Does Berberine help with Gut Dysbiosis?
Based on 2 studies with 100 participants, there is preliminary evidence that needs more research that Berberine may support Gut Dysbiosis management. Our evidence grade is D (Very Early Research).
How much Berberine should I take for Gut Dysbiosis?
Studies have used various dosages. A commonly studied range is 500-1,500 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Berberine?
Reported side effects may include GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common, May cause uterine contractions (contraindicated in pregnancy), Headache, Skin rash (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Berberine and Gut Dysbiosis?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 100 total participants. The overall direction of effect is positive.
Related Evidence
Altri ingredienti per Gut Dysbiosis
Berberine per altre condizioni
Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.